Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Lora Stojanovic
Institution:
University of Maryland, Baltimore
Observed institutions:
University of Maryland, Baltimore,
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
ORCID:
0000-0003-1347-6334
Observed ORCID:
0000-0003-1347-6334
OpenAlex ID:
A5060284740
DNA methyltransferase inhibitors induce a BRCAness phenotype that sensitizes NSCLC to PARP inhibitor and ionizing radiation
2019
·
Rachel Abbotts
, Michael J. Topper
, et al.
·
Proceedings of the National Academy of Sciences
·
104
Pharmacologic induction of innate immune signaling directly drives homologous recombination deficiency
2020
·
Lena J. McLaughlin
, Lora Stojanovic
, et al.
·
Proceedings of the National Academy of Sciences
·
41
Activating STING1-dependent immune signaling in TP53 mutant and wild-type acute myeloid leukemia
2022
·
Aksinija A. Kogan
, Michael J. Topper
, et al.
·
Proceedings of the National Academy of Sciences
·
26
PDF
ZNFX1 Functions as a Master Regulator of Epigenetically Induced Pathogen Mimicry and Inflammasome Signaling in Cancer
2025
·
Lora Stojanovic
, Rachel Abbotts
, et al.
·
Cancer Research
·
19
PDF
Combining STING Agonists with PARP Inhibitors Mounts an NK-Dependent Defense against Therapy-Resistant Breast Cancer
2025
·
Zahra Gohari
, Lora Stojanovic
, et al.
·
Cancer Research
·
11
Abstract 6301: DNA methyltransferase inhibitors increase ERV reactivation and STING-dependent interferon/inflammasome signaling in TP53 mutant AML
2022
·
Aksinija A. Kogan
, Michael J. Topper
, et al.
·
Cancer Research
·
1
BRCA1 at the Crossroads of Genome Stability, Mitochondrial Homeostasis, and Tumor Immunity
2026
·
Zahra Gohari
, Lora Stojanovic
, et al.
·
Clinical Cancer Research
STING agonists in combination with epigenetic drugs potentiate ZNFX1-driven inflammatory necroptosis in TP53 -mutated AML
2026
·
Kaushlendra Tripathi
, Lora Stojanovic
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
PDF
Abstract 2245: DNMTi in combination with PARPi inhibits aberrant Wnt/β-catenin signaling and tenasin-C pathways, cancer stemness and metastasis in triple negative breast cancer.
2026
·
Lora Stojanovic
, Kaushlendra Tripathi
, et al.
·
Cancer Research
Next generation sting agonist in combination with DNA methyltransferase inhibitors induce an apoptotic cell death mechanism driven by apoptosis in TP53-mutated Acute Myeloid Leukemia
2025
·
Lora Stojanovic
, Kaushlendra Tripathi
, et al.
·
Blood
PDF
Abstract B009: BRCA1 regulates ZNFX1-induced mitochondrial dysfunction and STING activation in high grade serous ovarian cancer
2025
·
Zahra Gohari
, Feyruz V. Rassool
, et al.
·
Cancer Research
Abstract 5865: Novel allosteric STING agonists in combination with DNA methyltransferase inhibitors induce an interferon-driven apoptotic response in TP53-mutated acute myeloid leukemia
2025
·
Kaushlendra Tripathi
, Lora Stojanovic
, et al.
·
Cancer Research
Supplementary Data from ZNFX1 Functions as a Master Regulator of Epigenetically Induced Pathogen Mimicry and Inflammasome Signaling in Cancer
2025
·
Lora Stojanovic
, Rachel Abbotts
, et al.
Data from ZNFX1 Functions as a Master Regulator of Epigenetically Induced Pathogen Mimicry and Inflammasome Signaling in Cancer
2025
·
Lora Stojanovic
, Rachel Abbotts
, et al.
Abstract PR001: ZNFX1 is a master regulator and tumor suppressor in epigenetically-induced pathogen mimicry, mitochondrial dysfunction and STING-dependent signaling in cancer
2025
·
Feyruz V Rassool
, Lora Stojanovic
, et al.
·
Cancer Research
Abstract 2838: ZNFX1 is a master regulator and tumor suppressor in epigenetically induced pathogen mimicry, mitochondrial dysfunction and STING-dependent signaling in cancer
2024
·
Lora Stojanovic
, Rachel Abbotts
, et al.
·
Cancer Research
Abstract PR-005: ZNFX1 is a master regulator for epigenetic reprograming of mitochondrial inflammasome signaling and pathogen mimicry in cancer cells
2024
·
Lora Stojanovic
, Rachel Abbotts
, et al.
·
Cancer Research
Abstract 5593: DNMT inhibitor induces NSCLC inflammasome signaling and mitochondrial dysfunction, producing to DSB repair defects and PARP inhibitor sensitivity
2022
·
Rachel Abbotts
, Lora Stojanovic
, et al.
·
Cancer Research
Abstract 1422: Enhancing the therapeutic effects of PARP inhibitors in combination DNA methyl transferase inhibitors, using low doses of ionizing radiation in non small cell lung cancers
2017
·
Christopher Biondi
, Daniel Fontaine
, et al.
·
Cancer Research
Show more works
View as search
Works count:
19
Citation count:
202
H-index:
5
I10-index:
5
Year
Topic
Type